Taiho Pharmaceutical Co., Ltd. / Araris Biotech AG
2025 · Acquisition/Merger · $1.1B · Complete
Announcement Sentiment
95
Strongly positive
Taiho (subsidiary of Otsuka) agreed to acquire Araris Biotech for $400M upfront and up to $740M in milestones. Deal brings AraLinQ proprietary ADC linker platform and three preclinical ADC products for hematological and solid tumors. Follows a 2023 research collaboration. Update (Apr 2026): the acquisition closed and the first AraLinQ-platform asset reached the clinic — Taiho Oncology advanced ARC-02, a CD79b-targeting MMAE ADC for non-Hodgkin lymphoma, into a Phase 1 dose-escalation trial following FDA IND clearance, the first human test of the AraLinQ platform.